Answers are grounded in this paper and cite their sources.
Clinical respiratory review reveals updated strategies for medication escalation in adults with asthma, suggesting practical applications.
Asthma action plans (AAPs) are a cornerstone of asthma self-management support and are consistently associated with reduced exacerbations, improved quality of life and decreased health-care utilization in adults. However, their real-world uptake remains limited, with clinicians frequently citing uncertainty about how to operationalize appropriate medication escalation during acute loss of asthma control (the “yellow zone”). Since the original publication of the Canadian Thoracic Society-endorsed tool for yellow zone dose escalation, several new inhaler formulations, devices and combination therapies have entered the market. In addition, updated international guidelines and randomized controlled trial findings now converge on a strong recommendation to quadruple inhaled corticosteroid (ICS) doses as a strategy to prevent progression to severe exacerbation. This Clinical Respiratory Review synthesizes the evidence informing yellow zone instructions within AAPs and describes how we updated the point-of-care tool to accommodate new device types and therapeutic combinations. We briefly outline our approach to identifying relevant evidence, then summarize updated yellow zone escalation guidance for monotherapy ICS, ICS/long-acting beta-agonist (LABA), and ICS/LABA/long-acting muscarinic antagonist (LAMA) regimens across Canada, the United States and Europe, describing key pharmacologic principles and practical considerations such as dose-equivalence across devices, regulatory limits and safety data supporting short-term ICS escalation. Finally, we provide actionable advice for clinical practice and highlight priorities for future research.
No takes yet. Share an insight, caveat, or question.
Kouri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: